At Nousynapse Pharmaceuticals, we pioneer advancements in neurodegenerative disease.

Illuminating the Path to Preserving Cognitive Function

We target a pivotal mechanism responsible for synaptic loss and cognitive decline in disorders such as Alzheimer’s disease and Multiple Sclerosis.

Unmatched Discovery-to-Approval Expertise

By combining advanced, cutting-edge drug development techniques with carefully planned and strategic regulatory pathways, we aim to comprehensively tackle the significant unmet needs within CNS therapeutics. Supported by a world-class team of experts and strong collaborations with leading institutions, Nousynapse Pharmaceuticals is uniquely poised to shape the future landscape of neurodegenerative disease treatment and significantly improve millions of lives around the globe.

Strategic Regulatory Engagement

We utilize the FDA’s Model-Informed Drug Development Program to ensure efficient, evidence-based regulatory pathways and optimized drug development timelines.

AI-Driven Drug Discovery

Our proprietary platform expedites the development of first-in-class therapeutics designed to prevent detrimental synaptic pruning.

Novel Synaptic Targeting

We pioneer a revolutionary and transformative approach to treating neurodegenerative diseases by specifically addressing harmful synaptic pruning, a damaging process that is reactivated as a result of chronic brain inflammation. This innovative strategy effectively preserves essential synaptic function and protects long-term cognitive health.

Expert Leadership and Collaborative Network

Our multidisciplinary team of seasoned scientists and clinicians is supported by leading advisors and strategic industry partnerships, driving forward transformative treatments for neurodegenerative conditions.